Evidence map›Paper›PMID 41739729›Full record

ArticleChemMedChem2026

Gram-Scale Synthesis of an Arylsulfonamide-Type Alkaline Phosphatase Inhibitor.

Zsolt Rapi, Krisztina Fülöp, Zoltán Mucsi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zsolt RapiDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology Budapest University of Technology and Economics, Budapest, Hungary.ORCID https://orcid.org/0000-0002-6035-5482
Krisztina FülöpInstitute of Molecular Life Sciences, Research Centre for Natural Sciences, Hungarian Research Network, Budapest, Hungary.ORCID https://orcid.org/0000-0002-7453-6014
Zoltán MucsiBrainVisionCenter Ltd., Budapest, Hungary.ORCID https://orcid.org/0000-0003-3224-8847

Funding

Nemzeti Kutatási Fejlesztési és Innovációs Hivatal OTKA 127957Nemzeti Kutatási Fejlesztési és Innovációs Hivatal R01AR072695
6 · The paper itself

Abstract

Alkaline phosphatases (ALP) are present in most living organisms. This family of metalloenzymes catalyzes transphosphorylation reactions and hydrolyzes phosphate monoesters. ALP enzymes have significant roles in several physiological processes and disease states. Inhibition of these enzymes makes it possible to prevent or treat certain diseases, and their role in normal physiology can also be examined. Several inhibitors with diverse chemical structures have been reported. One of them, known as SBI-425, has a low IC

Indexed as

Alkaline PhosphataseEnzyme InhibitorsSulfonamidesAnimalsDose-Response Relationship, DrugMiceMolecular StructureStructure-Activity RelationshipAlkaline PhosphataseEnzyme InhibitorsSulfonamidesalkaline phosphataseinhibitorscalabilitysynthesis

Identifiers

PMID41739729
PMCPMC12935166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.